Abstract
In the present study, we demonstrate that recombinant human secretory leukocyte protease inhibitor (rhSLPI) inhibits infection of lymphocyte- and monocyte-derived tumor cell lines and peripheral blood lymphocytes with laboratory-adapted isolates and with the primary isolate, NDK, of free human immunodeficiency virus type 1 (HIV-1). In contrast, rhSLPI did not exhibit inhibitory activity toward transcytosis of cell-associated HIV-1 through a tight monolayer of endometrial epithelial cells. These observations indicate that the inhibitory effect of SLPI is restricted to free HIV-1 in corporal fluids.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Acquired Immunodeficiency Syndrome / immunology
-
Acquired Immunodeficiency Syndrome / prevention & control
-
Acquired Immunodeficiency Syndrome / transmission*
-
Cervix Uteri / cytology
-
Cervix Uteri / virology
-
Epithelial Cells / drug effects
-
Epithelial Cells / metabolism
-
Epithelial Cells / virology
-
Female
-
Gene Expression / immunology
-
HIV Seronegativity
-
HIV-1*
-
Humans
-
Lymphocytes / drug effects
-
Lymphocytes / metabolism
-
Lymphocytes / virology*
-
Monocytes / drug effects
-
Monocytes / metabolism
-
Monocytes / virology*
-
Proteinase Inhibitory Proteins, Secretory
-
Proteins / genetics
-
Proteins / immunology
-
Proteins / pharmacology*
-
RNA, Messenger / analysis
-
Recombinant Proteins / pharmacology
-
Secretory Leukocyte Peptidase Inhibitor
-
Serine Proteinase Inhibitors / immunology
-
Serine Proteinase Inhibitors / pharmacology*
-
Tight Junctions / metabolism
-
Tight Junctions / virology
Substances
-
Proteinase Inhibitory Proteins, Secretory
-
Proteins
-
RNA, Messenger
-
Recombinant Proteins
-
SLPI protein, human
-
Secretory Leukocyte Peptidase Inhibitor
-
Serine Proteinase Inhibitors